# US 2009/0263453 A1 · Methods and Compositions for Treating Pain Comprising a Statin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0263453 A1
- Document ID: US20090263453A1
- Status: Published application
- Kind: A1
- Application number: 12/105,809
- Filed: 2008-04-18
- Published: 2009-10-22
- Earliest claimed: 2008-04-18
- Assignees: Warsaw Orthopedic, Inc.
- Inventors: William McKay; John Zanella
- Web page: https://patentgrep.com/patent/US20090263453A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61K 31/351: not condensed with another ring
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin.

## Claims

### Claim 1

A method of treating or preventing pain and/or inflammation from sciatica, stenosis or spondilothesis in a patient in need of such treatment, the method comprising locally administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof at or near a target tissue site beneath the skin of the patient to treat or prevent sciatic pain and/or inflammation.

### Claim 2 (depends on 1)

A method of treating or preventing pain and/or inflammation according to claim 1, wherein the statin is administered by local injection or infusion.

### Claim 3 (depends on 1)

A method of treating or preventing pain and/or inflammation according to claim 1, wherein the method comprises locally administering one or more drug depots comprising the therapeutically effective amount of the statin or pharmaceutically acceptable salt thereof, the drug depot capable of releasing an effective amount of a statin or pharmaceutically acceptable salt thereof at or near the target tissue site.

### Claim 4 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the drug depot is biodegradable and releases an effective amount of a statin or pharmaceutically acceptable salt thereof over a period of at least one day to 6 months.

### Claim 5 (depends on 1)

A method of treating or preventing pain and/or inflammation according to claim 1, wherein the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal.

### Claim 6 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the drug depot is administered at one more target tissue sites at or near the sciatic nerve.

### Claim 7 (depends on 1)

A method of treating or preventing pain and/or inflammation according to claim 1, wherein the statin comprises at least cerivastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, rosuvastatin, eptastatin, pitavastatin, velostatin, fluindostatin, dalvastain, or pharmaceutically acceptable salts thereof or a combination thereof.

### Claim 8 (depends on 1)

A method of treating or preventing pain and/or inflammation according to claim 1, wherein the statin comprises lovastatin and is administered at a dose of about 0.3 mg/kg/day to about 3 mg/kg/day.

### Claim 9 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the drug depot releases 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the statin or pharmaceutically acceptable salt thereof relative to a total amount of statin loaded in the drug depot over a period of one day to 6 months after the drug depot is administered to the target tissue site.

### Claim 10 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the drug depot releases 40 ng to about 5 mg of the statin or pharmaceutically acceptable salt thereof every hour to treat or prevent sciatic pain and/or inflammation.

### Claim 11 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the drug depot comprises at least one anti-inflammatory or analgesic agent, at least one anabolic or an anti-catabolic growth factor or a combination thereof.

### Claim 12 (depends on 3)

A method of treating or preventing pain and/or inflammation according to claim 3, wherein the statin or pharmaceutically acceptable salt thereof is encapsulated in a plurality of depots comprising microparticles, microspheres, microcapsules, and/or microfibers suspended in a gel.

### Claim 13

A method of reducing pain and/or inflammation from sciatica, stenosis or spondilothesis in a patient in need of such treatment, the method comprising locally administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof at or near a target tissue site beneath the skin of the patient.

### Claim 14 (depends on 13)

A method of reducing pain and/or inflammation according to claim 13, wherein the statin is administered by local injection or infusion.

### Claim 15 (depends on 13)

A method of treating or preventing pain and/or inflammation according to claim 13, wherein the method comprises locally administering one or more drug depots comprising the therapeutically effective amount of the statin or pharmaceutically acceptable salt thereof, the drug depot capable of releasing an effective amount of a statin or pharmaceutically acceptable salt thereof at or near the target tissue site.

### Claim 16 (depends on 15)

A method of reducing pain and/or inflammation according to claim 15, wherein one or more drug depots release an effective amount of a statin or pharmaceutically acceptable salt thereof over a period of one day to 6 months.

### Claim 17 (depends on 13)

A method of reducing pain and/or inflammation according to claim 13, wherein the statin comprises at least cerivastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, rosuvastatin, pitavastatin, velostatin, fluindostatin, dalvastain, or pharmaceutically acceptable salts thereof or a combination thereof.

### Claim 18

An implantable drug depot useful for reducing, preventing or treating pain and/or inflammation in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof, the depot being implantable at a site beneath the skin to reduce, prevent or treat pain and/or inflammation, wherein the drug depot is capable of releasing an effective amount of a statin or pharmaceutically acceptable salt thereof over a period of at least one day.

### Claim 19 (depends on 18)

An implantable drug depot according to claim 18, wherein the drug depot is biodegradable and comprises (i) one or more immediate release layer(s) that releases a bolus dose of the statin or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) one or more sustain release layer(s) that releases an effective amount of the statin or pharmaceutically acceptable salt thereof over a period of one day to 6 months.

### Claim 20 (depends on 18)

An implantable drug depot according to claim 18, wherein the one or more immediate release layer(s) comprise poly (lactide-co-glycolide) (PLGA) and the one or more sustain release layer(s) comprise polylactide (PLA).
